Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcellx, Inc. stock logo
ACLX
Arcellx
$115.07
$114.67
$47.86
$115.13
$6.73B0.251.50 million shs14.67 million shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$31.14
+0.5%
$29.01
$25.52
$40.87
$1.80B0.97870,612 shs58,339 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$8.40
-1.3%
$8.00
$1.95
$12.43
$8.84B0.0231.08 million shs3.72 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$33.42
+1.2%
$40.93
$32.92
$57.81
$6.89B0.642.29 million shs377,211 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcellx, Inc. stock logo
ACLX
Arcellx
0.00%0.00%+0.21%+66.89%+99.19%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.00%-2.64%+7.27%-16.42%-8.99%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%+19.69%+16.90%+22.80%+311.11%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%-3.47%-19.19%-34.88%-25.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcellx, Inc. stock logo
ACLX
Arcellx
$115.07
$114.67
$47.86
$115.13
$6.73B0.251.50 million shs14.67 million shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$31.14
+0.5%
$29.01
$25.52
$40.87
$1.80B0.97870,612 shs58,339 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$8.40
-1.3%
$8.00
$1.95
$12.43
$8.84B0.0231.08 million shs3.72 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$33.42
+1.2%
$40.93
$32.92
$57.81
$6.89B0.642.29 million shs377,211 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcellx, Inc. stock logo
ACLX
Arcellx
0.00%0.00%+0.21%+66.89%+99.19%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.00%-2.64%+7.27%-16.42%-8.99%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%+19.69%+16.90%+22.80%+311.11%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%-3.47%-19.19%-34.88%-25.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcellx, Inc. stock logo
ACLX
Arcellx
2.11
Hold$111.87-2.78% Downside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
2.42
Hold$40.8931.31% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.86
Moderate Buy$14.2069.09% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.50
Moderate Buy$46.3838.77% Upside

Current Analyst Ratings Breakdown

Latest HRMY, IBRX, QGEN, and ACLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Set Price Target$12.00
5/8/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Boost Price TargetHold$25.00 ➝ $29.00
5/7/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Reiterated RatingHold$46.00 ➝ $40.00
5/5/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Reiterated RatingBuy$23.00
5/1/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
UpgradeStrong SellHold
4/30/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Reiterated RatingBuy$43.00
4/29/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
DowngradeHold (C)Hold (C-)
4/29/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Set Price TargetEqual Weight$44.00 ➝ $38.00
4/29/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Set Price TargetNeutralOutperform$53.00 ➝ $43.00
4/29/2026
Arcellx, Inc. stock logo
ACLX
Arcellx
Reiterated RatingNeutral
4/29/2026
Qiagen N.V. stock logo
QGEN
Qiagen
UpgradeStrong SellHold
(Data available from 5/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcellx, Inc. stock logo
ACLX
Arcellx
$22.29M301.95N/AN/A$6.96 per share16.53
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$868.45M2.08$3.19 per share9.75$15.11 per share2.06
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M77.64N/AN/A($0.51) per share-16.47
Qiagen N.V. stock logo
QGEN
Qiagen
$2.09B3.30$3.45 per share9.70$17.89 per share1.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcellx, Inc. stock logo
ACLX
Arcellx
-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%N/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$158.69M$2.4812.578.240.4316.20%17.19%11.99%N/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.85N/AN/AN/A-606.15%N/A-64.93%5/11/2026 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$424.88M$1.9117.4712.423.2919.16%14.09%8.26%N/A

Latest HRMY, IBRX, QGEN, and ACLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.76$0.55-$0.21$0.55$220.84 million$215.39 million
5/7/2026Q1 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million
5/6/2026Q1 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.54$0.54N/A$0.33$496.15 million$492.32 million
2/26/2026Q4 2025
Arcellx, Inc. stock logo
ACLX
Arcellx
-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million
2/24/2026Q4 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.84$0.38-$0.46$0.38$240.04 million$243.78 million
2/23/2026Q4 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.06+$0.02-$0.06N/A$38.29 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arcellx, Inc. stock logo
ACLX
Arcellx
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.260.78%N/A13.61%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcellx, Inc. stock logo
ACLX
Arcellx
N/A
4.44
4.44
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.15
3.58
3.56
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
5.10
5.08
Qiagen N.V. stock logo
QGEN
Qiagen
0.44
3.90
3.31

Institutional Ownership

CompanyInstitutional Ownership
Arcellx, Inc. stock logo
ACLX
Arcellx
96.03%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
Arcellx, Inc. stock logo
ACLX
Arcellx
8.35%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
11.00%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
69.48%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcellx, Inc. stock logo
ACLX
Arcellx
8058.48 million53.60 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.89 million51.53 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.05 billion319.65 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,654206.07 million187.53 millionOptionable

Recent News About These Companies

Qiagen (NYSE:QGEN) Hits New 1-Year Low - Time to Sell?
Qiagen (QGEN) Q1 2026 Earnings Transcript
Qiagen: Q1 Earnings Snapshot
QIAGEN Reports Full Results for Q1 2026
Qiagen (QGEN) Gets a Buy from DZ BANK AG

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcellx stock logo

Arcellx NASDAQ:ACLX

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$31.14 +0.15 (+0.48%)
As of 10:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$8.40 -0.11 (-1.32%)
As of 10:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$33.42 +0.38 (+1.15%)
As of 10:51 AM Eastern
This is a fair market value price provided by Massive. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.